Medicine and Dentistry
Patient
100%
Combination Therapy
50%
Neoplasm
27%
Alisertib
23%
Therapeutic Procedure
21%
Diseases
19%
Inpatient
17%
Non-Hodgkin Lymphoma
16%
Malignant Neoplasm
15%
Adverse Event
14%
Pancreas Adenocarcinoma
13%
Gene
12%
Clinical Trial
12%
Rituximab
12%
Chemotherapeutic Agent
11%
Drug
11%
Next Generation Sequencing
11%
B-Cell Chronic Lymphocytic Leukemia
11%
Peripheral T-Cell Lymphoma
11%
Diffuse Large B-Cell Lymphoma
10%
Cells
10%
Ibrutinib
10%
Multiple Myeloma
10%
Cancer
10%
Development
9%
B Cell
9%
T Cell
8%
Glioblastoma
8%
Amuvatinib
8%
Programmed Cell Death
8%
Drug Resistance
8%
Progression Free Survival
8%
Programmed Death-Ligand 1
8%
Aurora A Kinase
7%
Survival
7%
Multidrug Resistance
7%
Metastatic Colorectal Cancer
7%
Monoclonal Antibody
7%
Anemia
7%
Gemcitabine
6%
Ublituximab
6%
COVID-19
6%
Pembrolizumab
6%
Toxicity
6%
Phosphorylation
5%
Mantle Cell Lymphoma
5%
Bevacizumab
5%
Phosphotransferase Inhibitor
5%
Cancer Cell
5%
Imatinib
5%
Pharmacology, Toxicology and Pharmaceutical Science
Pancreas Adenocarcinoma
29%
Clinical Trial
29%
Malignant Neoplasm
26%
Neoplasm
25%
Diseases
23%
Alisertib
20%
Toxicity
20%
Nonhodgkin Lymphoma
17%
Drug
16%
Rituximab
15%
Solid Malignant Neoplasm
15%
Gemcitabine
13%
Chronic Lymphatic Leukemia
13%
Monoclonal Antibody
12%
Maximum Tolerated Dose
12%
Survival
12%
Aurora Kinase
12%
Adverse Event
12%
Multiple Myeloma
12%
Pharmacokinetics
11%
Tolerability
10%
Mouse
10%
[1 (4 Oxo 8 Phenyl 4h 1 Benzopyran 2 Yl)morpholinio]methoxysuccinylarginylglycylaspartylserine Acetate
10%
Hematologic Malignancy
9%
Chemotherapy
8%
Pancreas Cancer
8%
Diffuse Large B Cell Lymphoma
8%
Antitumor Activity
8%
Protein Serine Threonine Kinase
8%
DNA
8%
Vincristine
8%
Prostate Cancer
7%
Protein
7%
Apoptosis
7%
Docetaxel
7%
Pharmacodynamics
7%
Cancer Inhibition
7%
Glycine
7%
Pleckstrin
7%
Phosphotransferase
6%
Ublituximab
6%
Abrus
6%
Carcinoembryonic Antigen Related Cell Adhesion Molecule 6
6%
Glioblastoma
6%
Onalespib
6%
Inositol
6%
Imatinib
6%
Myelodysplastic Syndrome
6%
Bevacizumab
6%
Erlotinib
6%
Biochemistry, Genetics and Molecular Biology
Protein
16%
Nested Gene
16%
Pleckstrin Homology Domain
16%
Crystallin
13%
Mutation
12%
Kinase
12%
Development
11%
Dose
9%
B Cell
9%
Amino Acids
9%
C-Terminus
9%
Electric Potential
8%
N-Terminus
8%
DNA
7%
Clinical Trial
7%
Abrus
6%
Inositol
6%
Polyploid
6%
Survival
6%
Signal Transduction
6%
Mutant
6%
Sample
6%
Imatinib
6%
Insulin
5%
SH2 Domain
5%
Molecule
5%
Receptor Tyrosine Kinase
5%
Cancer Cell
5%
Phosphatidylinositol
5%
Apoptosis
5%
Comprehension
5%
Phosphorylation
5%
Small Molecule
5%
Gene Expression Profiling
5%